![]() Its heart is our Digital Imaging System, the breakthrough in detection technology that replaces the analogue photometer and produces significantly more detail for each MicroSlide reaction. The new VITROS® XT Systems utilize digital chemistry technology which enables the use of imaging algorithms to improve chemistry results. Through Digital Chemistry, Ortho is reimagining the power of technology throughout your lab and providing you with the confidence to meet the needs of patients today and the knowledge you are prepared for the demands of tomorrow. That is why Ortho is introducing the next generation in Clinical Chemistry solutions, Digital Chemistry. The world is digitizing rapidly to deliver enhanced patient care and satisfaction, more effective data, and increased efficiency. ![]() Ortho Products, Inc., is formed in Linden, New Jersey, as a division of Johnson & Johnson.ģF Twincity Namsan, 366, Hangangdae-ro, Yongsan-gu, Seoul, 04323, Korea +82-2-6222-3500 XT 7600 Integrated System Y1989 : Ortho Products introduces first test for the detection of antibodies to hepatitis C Ortho Clinical Diagnostics develops Ortho trak-C™, the world’s first branded “Total HCV Core Antigen” test designed to provide reliable measures of HCV viremia. Y2001 : Ortho Clinical Diagnostics becomes the first diagnostic company to receive US FDA approval for automated random access hepatitis tests, on the VITROS® ECi Immunodiagnostic System (for diagnostic use only not for blood screening). Ortho Clinical Diagnostics receives CE Mark for ORTHO VISION™ Analyzer, making it commercially available in Europe, Japan and Australia. The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson. ![]() Y2014 : The Carlyle Group acquires Ortho Clinical Diagnostics from Johnson & Johnson VITROS® High Sensitivity Troponin I assay gets CE Mark Multi-test technology allows labs to run two frequently ordered tests simultaneously on one slide. VITROS® XT Chemistry Product Slides (FDA) Solutions offer labs faster, more accurate results and trusted system reliability to ensure better patient outcomes. VITROS® XT 3400 Chemistry System Enhances Its VITROS® XT Solutions. ORTHO Optix™ Reader becomes available in CE Mark countries. ORTHO Optix™ Reader Completes Transfusion Medicine Portfolio. VITROS® XT Solutions Win Prestigious Global Edison Award for Innovation The company’s COVID-19 solutions for mass-scale testing include two COVID-19 antibody tests - Total and IgG - both of which have FDA EUA and CE Mark, and an antigen test. Ortho launched the first high-volume antibody and antigen tests authorized by the U.S. Y2020 : Ortho Launches VITROS® COVID-19 Testing Solutions Ortho Clinical Diagnostics was recognized with MedTech’s 2020 Outstanding Contribution to the Bio/Med Industry Award for its COVID-19 Testing Solutions. Ortho Care™ was recognized by the Stevie Awards for Exceptional Customer Service for the fifth years in a row. Ortho began trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol "OCDX". With a focus on innovation, commercial excellence and operational efficiency, our global leadership is relentless in its dedication to supporting customers and the patients they serve. Responsibility : Protecting the environment and advancing sustainability go hand-in-hand with our purpose of improving and saving lives through diagnostics. Food and Drug Administration-authorized high-volume antibody and antigen tests for COVID-19, Ortho has been a pioneering leader in the IVD space for over 80 years. Our Story : From launching the first product to determine Rh+ or Rh- blood type, developing the world’s first tests for the detection of antibodies against HIV and hepatitis C, introducing patented dry-slide technology and marketing the first U.S. Our customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs. We provide hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate and reliable. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohematology communities. Who We Are : Ortho Clinical Diagnostics is a leading global provider of in vitro diagnostics. We are proud to support over one million of these tests every day, impacting over 800,000 patients. Information gained from diagnostic tests is responsible for 70% of all medical decisions. Ortho Clinical Diagnostics (Nasdaq: OCDX) is one of the world’s largest pure-play in vitro diagnostics companies.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |